Amer Kazi, MD
Pain Medicine · Granger, INNPI 1134122914
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,050 of the $33,611 with a category attached, or 65.6%. 46 manufacturers reported payments, led by AbbVie at 28.8% of the total. Reporting peaked in 2021 at $15,020 and has fallen 93.3% since, to $1,007 in 2025. Among pain medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 698 payments — averaging $48.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Biohaven Pharmaceuticals, Inc.$9K
- Biohaven Pharmaceutical Holding Company Ltd.$7K
- Teva Pharmaceuticals USA, Inc.$902
- Scilex Pharmaceuticals Inc.$664
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$657
- plus $6K from 40 others
What the payments were for
- Speaking & faculty fees$22,05066%
- Travel & lodging$930%
- Food & beverage$11,25233%
- Education$2161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$14,608
- UBRELVY$7,675
- AIMOVIG$125
How this compares
$33,611 in reported general payments places this provider in the 90th percentile of 128 pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $118,373 |
| Nurtec OdtRimegepant Sulfate | 54 | $56,892 |
| UbrelvyUbrogepant | 52 | $47,044 |
| RelistorMethylnaltrexone Bromide | 25 | $45,302 |
| Xtampza ErOxycodone Myristate | 59 | $45,236 |
| Emgality PenGalcanezumab-Gnlm | 37 | $25,431 |
| ZtlidoLidocaine | 63 | $24,813 |
| NucyntaTapentadol Hcl | 33 | $18,502 |
| QuliptaAtogepant | 16 | $16,965 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $12,730 |
| BelsomraSuvorexant | 30 | $11,742 |
| Nucynta ErTapentadol Hcl | 14 | $11,498 |
| Lidocaine | 113 | $9,952 |
| BelbucaBuprenorphine Hcl | 12 | $9,783 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 436 | $6,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $494 | $118,37315 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Nucynta Er, Belbuca | $504 | $85,019118 claims |
| AbbVieUbrelvy, Qulipta | $9,695 | $64,00968 claims |
| PfizerNurtec Odt | $604 | $56,89254 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $657 | $45,30225 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $664 | $24,81363 claims |
| MerckBelsomra | $138 | $11,74230 claims |
| Upsher-smith Laboratories LLCTopiramate | $369 | $1,580292 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 128 pain medicine providers in Indiana.
Other pain medicine in Granger
- Derron WilsonCarmel$616K
- Kevin MacadaegCarmel$337K
- Andrew TrobridgeMuncie$253K
- Meredith LanghorstFishers$233K
- Abhishek DasMishawaka$186K
- Rajiv TewariFishers$140K
- John SwoffordIndianapolis$127K
- Neal ColemanMuncie$38K
- Matthew DevriesLafayette$37K
- Sheel PatelPortage$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.